• Global Q1 sales AUD$2.0 million up 34% on prior comparative period
• Australia Q1 sales AUD$1.6 million up 52% on prior comparative period
• USA Q1 sales AUD$0.4 million up 44% on prior comparative period

Immuron Limited, an Australian based and globally integrated biopharmaceutical company, announced continued sales growth (unaudited) of Travelan, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. Global Q1 sales were AUD$2.0 million, up 34% on the prior comparative period. In Australia, Q1 sales were AUD$1.6 million, up 52% on the prior comparative period, driven by increased awareness and consideration through digital and social media marketing, same-store growth from increased promotion and past promotions driving new and returning customers, growth from new stores within banner groups, and increased South East Asian travel. Q1 sales in the U.S. increased 44% on the prior comparative period, on the back of marketing initiatives including an improved Travelan store on Amazon.com, local U.S. Travelan Facebook and Instagram pages, and increased paid social, influencer and organic social media marketing. Q1 sales in Canada, typically the lowest travel period, were down 92% on the prior comparative period, but are expected to pick up towards the end of the calendar year when travel typically increases, as the company continues to build Travelan brand awareness through in-store educational programs, promotions, and social media marketing.